Dr Finn explained that pre-clinical studies identified that ER+ breast cancer models were most sensitive to growth inhibition with palbociclib and identified a synergistic interaction in inhibiting proliferation in combination with tamoxifen [1]. Here, ESR1 is linked to breast cancer.